Clinical trials: Sleep Disturbances in Children

Insomnia, Attention Deficit Hyperactivity Disorder

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

• Completed
• Age: 6 to 17 years
• Phase 3
• Results posted

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

Trial name

NCT00857220

Testing

eszopiclone

Where

89 sites in United States

Volunteers

304 people

Sponsor

Sumitomo Pharma America, Inc.